Cholangiocarcinoma in real life

Cholangiocarcinoma is a rare and aggressive hepatobiliary malignancy, whose incidence is increasing and for which treatment options are developing. Yet real-life data are lacking to better address the clinical challenges of this tumor. In this multicenter study, researchers analyzed data from 120 patients with metastatic cholangiocarcinoma, with a mean age of 68.5 years. In 65.8% of cases, intrahepatic tumours predominated. Among the 85 patients treated with first-line chemotherapy, cisplatin and gemcitabine were the most common regimens. After a median follow-up of 14 months, 81 cholangiocarcinoma-related deaths were recorded, with a median survival of 13.1 months.